NO20090164L - Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA - Google Patents

Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA

Info

Publication number
NO20090164L
NO20090164L NO20090164A NO20090164A NO20090164L NO 20090164 L NO20090164 L NO 20090164L NO 20090164 A NO20090164 A NO 20090164A NO 20090164 A NO20090164 A NO 20090164A NO 20090164 L NO20090164 L NO 20090164L
Authority
NO
Norway
Prior art keywords
slv308
dopa
preparations including
combination preparations
simultaneous
Prior art date
Application number
NO20090164A
Other languages
English (en)
Inventor
Gustaaf Johan Marie Van Scharrenburg
Martinus Th M Tulp
Andrew C Mccreary
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20090164L publication Critical patent/NO20090164L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår anvendelsen av et kombinasjonspreparat av SLV308 eller dets N-oksid, eller farmakologisk akseptable salter av disse forbindelsene (I), (II) og L-DOPA, for samtidig, separat eller sekvensiell anvendelse i behandlingen av lidelser som krever gjenvinning av dopaminergisk funksjon, spesielt Parkinsons sykdom og rastløse ben syndrom.
NO20090164A 2006-06-16 2009-01-12 Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA NO20090164L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405106P 2006-06-16 2006-06-16
EP06115583 2006-06-16
PCT/EP2007/055955 WO2007144421A1 (en) 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a l-dopa

Publications (1)

Publication Number Publication Date
NO20090164L true NO20090164L (no) 2009-01-14

Family

ID=38434785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090164A NO20090164L (no) 2006-06-16 2009-01-12 Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA

Country Status (10)

Country Link
EP (1) EP2035002A1 (no)
JP (1) JP2009539941A (no)
KR (1) KR20090031908A (no)
AU (1) AU2007259255A1 (no)
CA (1) CA2654719A1 (no)
EA (1) EA015073B1 (no)
IL (1) IL195532A0 (no)
MY (1) MY148457A (no)
NO (1) NO20090164L (no)
WO (1) WO2007144421A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7596407B2 (en) * 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
ATE417834T1 (de) * 2005-08-22 2009-01-15 Solvay Pharm Bv N-oxide als prodrugs von piperazin- und piperidinderivaten

Also Published As

Publication number Publication date
MY148457A (en) 2013-04-30
EP2035002A1 (en) 2009-03-18
KR20090031908A (ko) 2009-03-30
AU2007259255A1 (en) 2007-12-21
JP2009539941A (ja) 2009-11-19
IL195532A0 (en) 2009-09-01
CA2654719A1 (en) 2007-12-21
EA015073B1 (ru) 2011-04-29
WO2007144421A1 (en) 2007-12-21
EA200970021A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NO20090165L (no) Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
NO20084752L (no) Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
NO20090591L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20085099L (no) Puritonderivativer som HM74A agonister
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
NO20073651L (no) Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi
DK2013166T3 (da) N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
NO20090164L (no) Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA
UA92730C2 (ru) Аналоги бензазола и их применение
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2007128924A3 (fr) Extrait aqueux de feuilles de tabac , ses utilisations dans le traitement de la dependance
MX2010000120A (es) Estereoisomeros de triciclodecan-9-il-xantogenato.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application